...speculation that the advisory committee will act sensibly. I think it will as there are many gastros among the committee members and they are already using Rifaximin off-label in 2nd line in HE. http://www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/GastrointestinalDrugsAdvisoryCommittee/UCM200985.pdf